Buy TB-500 Online | ≥99% Purity Research Peptide | SourceTides

Buy TB-500 Online from SourceTides and receive a research-grade synthetic heptapeptide supplied at ≥99% purity, confirmed by reverse-phase HPLC and mass spectrometry on every production batch. TB-500 — formally designated Ac-LKKTETQ and also referenced as fequesetide or Thymosin Beta-4 fragment (17–23) — is a 7-amino-acid N-terminally acetylated peptide corresponding to the biologically active actin-binding domain of the endogenous 43-amino-acid protein Thymosin Beta-4 (Tβ4). Thymosin Beta-4 was first isolated from bovine thymus tissue and has since been identified as one of the most abundant and highly conserved intracellular peptides in mammalian biology, found in virtually every tissue and cell type except red blood cells.

TB-500’s 7-residue active fragment (residues 17–23 of the full Tβ4 sequence) was identified as the minimal sequence sufficient for actin binding and cell migration stimulation. Its small molecular size (~889 g/mol) confers pharmacokinetic advantages over the full-length parent molecule — notably rapid tissue penetration, systemic distribution following subcutaneous or intravenous administration in preclinical models, and resistance to extracellular matrix binding, allowing broader tissue distribution than larger growth factor molecules.

Every SourceTides TB-500 vial ships with a batch-specific Certificate of Analysis (CoA) and is handled under cold-chain packaging conditions. This product is supplied exclusively for in-vitro and laboratory research purposes only and is not approved by the FDA, EMA, or any regulatory authority for human therapeutic or veterinary use.

TB-500 Research Peptide — Full Technical Specifications

The table below consolidates the key physicochemical and handling parameters researchers require before sourcing TB-500 for a preclinical study protocol.

What Is TB-500? Origins, Parent Molecule, and Research Context

TB-500 is a synthetic heptapeptide — seven amino acids in length — engineered to replicate the biologically active actin-binding region of Thymosin Beta-4. Understanding what TB-500 is requires first understanding its parent molecule.

Thymosin Beta-4 (Tβ4) is a 43-amino-acid highly conserved, water-soluble peptide first isolated from bovine thymus tissue and later found to be one of the most abundant intracellular peptides in the mammalian body. It is present in high concentrations in blood platelets, neutrophils, macrophages, and lymphoid tissues. Tβ4’s primary intracellular function is the regulation of actin polymerisation — it sequesters globular actin (G-actin) monomers and buffers the free actin pool, which in turn governs cell motility, cytoskeletal architecture, organogenesis, and tissue repair signalling. A 2007 PubMed review (Bock-Marquette and Bhatt, Current Pharmaceutical Design) described Tβ4 as a “highly conserved, 43-amino acid acidic peptide” playing numerous physiological roles, most prominently the regulation of actin polymerisation with downstream effects on cell motility, organogenesis, and other important cellular events. (PubMed — Tβ4 ischemic heart disease development, 2007)

TB-500 specifically corresponds to residues 17–23 (Ac-LKKTETQ) — the minimal sequence within Tβ4 sufficient for actin binding and cell migration stimulation. Its N-terminal acetylation (the “Ac-” prefix) provides protection against enzymatic degradation, improving stability in biological systems. Because of its dramatically smaller size (~889 g/mol vs. ~4,963 g/mol for full-length Tβ4), TB-500 offers distinct pharmacokinetic characteristics in preclinical models, including rapid tissue penetration and systemic distribution unimpeded by extracellular matrix binding. (Wikipedia — TB-500 identity and classification)

Researchers should note that TB-500 (the 7-AA fragment) and full-length Thymosin Beta-4 (the 43-AA parent) are distinct molecules with different structures, molecular weights, and pharmacokinetic profiles. Clinical trial data from Tβ4 studies (including Phase II dermal wound and corneal injury trials) cannot be directly extrapolated to TB-500 without independent evidence. This distinction is critical for rigorous research methodology.

TB-500 Mechanism of Action — How It Works at the Molecular Level

TB-500 exerts its biological effects through several interconnected pathways, all rooted in its fundamental role as an actin-binding and G-actin sequestering peptide.

G-Actin Sequestration and Cytoskeletal Regulation

The defining molecular function of TB-500 is the sequestration of globular actin (G-actin) monomers. Actin polymerisation — the assembly of G-actin monomers into filamentous actin (F-actin) — is the engine that drives cell shape changes, cell division, and directed cell migration. By binding and buffering the free G-actin pool, TB-500 governs the dynamic balance between G-actin and F-actin, thereby modulating cytoskeletal remodelling. This is the mechanism underlying the cell migration and wound closure effects consistently observed in preclinical models. (ScienceDirect — Thymosin Beta-4 G-actin sequestering overview)

Cell Migration Enhancement

The LKKTETQ actin-binding motif directly promotes directed cell migration across multiple cell types studied in preclinical models — including keratinocytes, fibroblasts, endothelial cells, and muscle satellite cells (myoblasts). A PubMed-indexed study (Ueda et al., Journal of Cell Science, 2010) demonstrated that Tβ4 and its sulphoxidised form significantly accelerated wound closure and increased chemotaxis of C2C12 myoblastic cells, and that primary myoblasts derived from adult muscle satellite cells were chemoattracted to the sulphoxidised form of Tβ4, indicating a role for this peptide axis in muscle injury-triggered regenerative cell recruitment. (PubMed — Thymosin β4 muscle injury chemoattractant, 2010)

Angiogenesis — Endothelial Cell Differentiation and Blood Vessel Formation

TB-500 promotes endothelial cell differentiation and angiogenesis in dermal and other tissue models. Through its capacity to stimulate endothelial cell migration, it supports new blood vessel formation — including in poorly vascularised tissues such as cartilage. This proangiogenic activity is mechanistically linked to its actin-regulation effects on endothelial cytoskeletal dynamics and is consistent with the broader Tβ4 literature on angiogenesis. (MedKoo — TB-500 endothelial differentiation and angiogenesis)

PINCH–ILK–Akt Survival Pathway (Cardiac Models)

In cardiac preclinical models, Thymosin Beta-4 (the parent molecule) has been shown to form a functional complex with PINCH and integrin-linked kinase (ILK), resulting in activation of the survival kinase Akt/PKB — a critical pro-survival signalling cascade. A landmark 2007 PubMed study (Bock-Marquette et al., Nature and follow-up publications) demonstrated that after coronary artery ligation in mice, Tβ4 treatment upregulated ILK and Akt activity in the heart, enhanced early myocyte survival, and improved cardiac function. These findings established the cardioprotective mechanistic framework being investigated in subsequent Tβ4-derivative research. (PubMed — Thymosin beta4 cardioprotective after MI, 2007)

Collagen Deposition and Anti-Fibrotic Activity

TB-500 and the parent Tβ4 molecule promote collagen deposition at wound sites while simultaneously reducing the number of myofibroblasts — the fibre-forming cells responsible for scar tissue formation. This dual action — accelerating extracellular matrix reconstruction while limiting excessive scarring — is a significant research focus. A 2024 Medical Anti-Aging review synthesising multiple rat model studies noted that after 14 days of treatment with 100 µg Tβ4 administered post-incision, treated animals showed thicker and longer collagen fibre bundles, more significant wound width reduction, and less scarring compared to controls. (Medical Anti-Aging — TB-500 collagen and scarring evidence review 2024)

Anti-Inflammatory Cytokine Modulation

Thymosin Beta-4 and its fragments demonstrate the capacity to down-regulate inflammatory chemokines and cytokines in preclinical models. This anti-inflammatory activity operates alongside the proangiogenic and cell-migration effects, contributing to a tissue environment that supports regeneration over chronic inflammation. A PubMed review (Kleinman et al.) summarising animal model studies supporting Tβ4’s multiple biological activities specifically listed down-regulation of inflammatory chemokines and cytokines alongside promotion of cell migration, blood vessel formation, cell survival, and stem cell maturation as core activities. (PubMed — Tbeta4 animal studies multi-function tissue repair 2010)

Keratinocyte Migration and Dermal Wound Healing

Keratinocytes — the primary cells of the skin epidermis — migrate across wound surfaces during re-epithelialisation, the critical first phase of skin wound closure. TB-500 promotes keratinocyte migration through its actin-mediated cytoskeletal effects, accelerating this essential healing step. This is one of the best-documented effects in the preclinical wound-healing literature for this peptide class. The parent Tβ4 molecule entered Phase II clinical trials for chronic wound healing (pressure ulcers, stasis ulcers, epidermolysis bullosa lesions) specifically on the basis of this dermal evidence base.

TB-500 Preclinical Research Areas — Evidence Summary Table

The following table maps the primary research domains investigated in the Tβ4 and TB-500 preclinical literature, along with the model types studied, proposed mechanisms, and source references. All data is from animal or in-vitro models unless otherwise stated.

Note: cardiac and corneal wound healing clinical data references full-length Thymosin Beta-4 (Tβ4), not TB-500 (the 7-AA fragment). These are distinct molecules. See the TB-500 vs Tβ4 distinction section below.

TB-500 vs. Full-Length Thymosin Beta-4 — An Important Research Distinction

One of the most important methodological considerations when designing TB-500 research protocols is understanding the distinction between TB-500 (Ac-LKKTETQ, residues 17–23, ~889 g/mol) and full-length Thymosin Beta-4 (Tβ4, 43 amino acids, ~4,963 g/mol). These are different molecules with different molecular weights, three-dimensional structures, pharmacokinetic profiles, and potentially different downstream biological effects.

Clinical data from Tβ4 studies (Phase II wound and corneal trials) cannot be directly cited as evidence for TB-500 without independent experimental validation. A 2025 detailed analysis (Peptidings.com TB-500 review) correctly notes that a 7-word excerpt from a 43-word sentence does not carry all the meaning of the full sentence — the additional regions of Tβ4 may contribute independently to biological effects beyond those of the 17–23 fragment.

TB-500 Pharmacokinetics — Distribution, Stability and Tissue Penetration

TB-500’s pharmacokinetic profile in preclinical models is shaped by three defining physical characteristics: its small molecular size (~889 g/mol), its N-terminal acetylation, and the absence of extracellular matrix binding capacity (unlike larger growth factors that are sequestered at injection sites by ECM proteins).

High-Purity TB-500 for Sale — SourceTides Quality Control

Research-grade purity is non-negotiable when sourcing TB-500. Impure peptide preparations introduce uncontrolled variables — undeclared peptide fragments, residual synthesis by-products, or endotoxin contamination — that can confound cellular assay results and invalidate experimental conclusions. SourceTides applies a multi-stage quality verification process to every TB-500 batch before dispatch.

TB-500 Regulatory and Legal Status — 2025 Overview

View SourceTides’ full shipping and compliance policy.

Buy TB-500 Online vs. Other Research Peptides — Side-by-Side Comparison

TB-500 and Thymosin Beta-4 Peer-Reviewed Research References

Frequently Researched Alongside TB-500 — SourceTides Catalogue

Researchers studying TB-500 commonly pair it with complementary peptides in musculoskeletal repair, angiogenesis, or wound healing protocols. Browse the full SourceTides research peptide catalogue:

• BPC-157 (Body Protection Compound-157) — GI protection & musculoskeletal repair research — the most commonly paired peptide with TB-500 in repair research protocols
• Sermorelin — Growth hormone secretagogue research
• CJC-1295 — Long-acting GH analog research peptide
• Ipamorelin — Selective GH secretagogue, minimal off-target signalling
• Browse All Research Peptides — SourceTides full catalogue
• SourceTides Peptide Research Guide — Protocol design & reference resources

Frequently Asked Questions — Buy TB-500 Online